



Docket No.: PS735

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Rosen et al.

Application No.: 10/644,807

Confirmation No.: 7993

Filed: August 21, 2003

Art Unit: 1646

For: Antibodies To HQAHD50 Polypeptide (As
Amended Herein)

Examiner: X. Xie

INFORMATION DISCLOSURE STATEMENT (IDS)

MS Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure imposed by 37 C.F.R. § 1.56 to inform the Patent and Trademark Office of all references coming to the attention of each individual associated with the filing or prosecution of the subject application, which are or may be material to the patentability of a claim of the subject application, Applicants hereby direct the Examiner's attention to references AA-AI listed on the attached Form PTO/SB/08. A copy of each of references AA-AI is enclosed.

For the Examiner's convenience, Applicants note that references AA-AE were cited in European Search Reports (references AF and AG) in a counterpart European patent application in relation to SEQ ID NOS: 11 and 198, as well as, SEQ ID NOS: 12-384 (*See*, "Sheet B" in references AF and AG).

The above information is presented so that the Patent and Trademark Office can determine any materiality thereof to the claimed invention. See 37 CFR § 1.104(a) concerning the PTO duty to consider and use any such information. It is respectfully requested that the information be considered during the prosecution of this application.

Identification of the listed references is not to be construed as an admission of any individual associated with the filing or prosecution of the subject application that such references are available as "prior art" against the subject application. Furthermore, Applicants do not waive any rights to appropriate action to establish patentability over any of the listed documents should they be applied as references against the claims of the subject application.

Pursuant to 37 C.F.R. § 1.97(b), since this information disclosure statement is being filed before the mailing date of a first Office Action on the merits, no fee is due in connection herewith. However, should the Patent Office determine otherwise, please charge the required fee to Human Genome Sciences, Inc., deposit account no. 08-3425. If a fee is required for an extension of time under 37 C.F.R. § 1.136, such an extension is requested and the appropriate fee should also be charged to our Deposit Account.

Dated: October 17, 2005

Respectfully submitted,

By 

Doyle A. Siever

Registration No.: 47,088

HUMAN GENOME SCIENCES, INC.


Intellectual Property Dept.

14200 Shady Grove Road

Rockville, Maryland 20850

(301) 354-3932

Attorneys for Applicant



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/644,807
				Filing Date	August 21, 2003
				First Named Inventor	Craig A. Rosen
				Art Unit	1646
				Examiner Name	X. Xie
Sheet	1	of	1	Attorney Docket Number	PS735

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				
	AA	WO-9947540	09-23-1999	Human Genome Sciences, Inc		
	AB	WO-0177137	10-18-2001	Human Genome Sciences, Inc		
	AC	WO-0132675	05-10-2001	Human Genome Sciences, Inc		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	AD	GenBank Accession No. AL162731, CORBY, "Human DNA sequence." March 30, 2000 (abstract).	
	AE	GenBank Accession No. AAC55313, HONJO et al., "Human activation-induced cytidine deaminase genomic SEQ ID No. 9." October 5, 2000 (abstract).	
	AF	Partial European Search Report, Application No. EP 02 72 3191, mailed January 4, 2005.	
	AG	Supplementary Partial European Search Report, Application No. EP 02 72 3191, mailed September 22, 2004.	
	AH	OLSSON et al., "PRAC2: a new gene expressed in human prostate and prostate cancer." <i>Prostate</i> , 56(2):123-30 (2003).	
	AI	LIU et al., "PRAC: A novel small nuclear protein that is specifically expressed in human prostate and colon." <i>Prostate</i> , 47(2):125-31 (2001).	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--